Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Fbio save search
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 7.14%
H: 1.9%
C: -0.95%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -7.41%
t-cell expansion vision therapy platform
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
mb-101 publication trial
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 10.19%
H: 21.97%
C: -18.5%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.53%
H: 2.93%
C: -4.26%
mb-109 fda mb-101 cell treatment application car-t glioblastoma
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Published: 2023-10-16 (Crawled : 13:00) - globenewswire.com
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -4.43%
H: 3.6%
C: 3.6%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 0.34%
H: 4.12%
C: -4.81%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -1.07%
H: 2.0%
C: 1.82%
biotech worldwide hope cell treatment city agreement therapy living
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Published: 2023-08-16 (Crawled : 12:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 5.53%
H: 0.0%
C: -9.23%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 1372.45%
H: 1.87%
C: -3.85%
mb-106 cell ongoing car-t trial therapy
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
Published: 2023-05-11 (Crawled : 20:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 5.47%
H: 0.0%
C: -3.32%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.89%
H: 3.06%
C: 0.28%
mb-106 cell trial therapy
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
Published: 2022-12-19 (Crawled : 15:00) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 7.67%
H: 0.58%
C: -16.49%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.79%
H: 3.82%
C: -8.21%
therapy
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
Published: 2022-10-27 (Crawled : 12:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: -1.51%
H: 11.3%
C: 6.78%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.55%
H: 0.0%
C: -1.58%
mb-106 trial international
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Published: 2022-10-06 (Crawled : 13:20) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 1.96%
H: 1.88%
C: -3.85%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 1.33%
H: 6.7%
C: -1.03%
mb-106 leukemia trial therapy
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Published: 2022-04-25 (Crawled : 21:00) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 0.0%
H: 1.9%
C: 0.2%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: -0.93%
mb-106 leukemia phase 1
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
Published: 2022-04-13 (Crawled : 15:20) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: -1.1%
H: 14.29%
C: -0.99%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.87%
H: 1.75%
C: 0.88%
mb-101 treatment trial phase 1 glioblastoma
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2022-02-15 (Crawled : 14:00) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 1.69%
H: 5.15%
C: 5.15%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 1.09%
H: 2.15%
C: 1.08%
mb-105 america symposium state presentation cel stem cell cancer
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: -4.99%
H: 0.0%
C: 0.0%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
mb-106 leukemia phase 1 t-cell
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 2.88%
H: 1.87%
C: -3.27%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 4.85%
H: 0.0%
C: 0.0%
mb-106 treatment leukemia potential lymphomas t-cell
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 0.45%
H: 6.22%
C: 5.78%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.61%
H: 6.17%
C: 6.17%
treatment therapy car-t t-cell
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 4.99%
H: 1.5%
C: -5.25%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
phase 1 leukemia phase 3 car-t t-cell
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 1.65%
H: 4.24%
C: 0.58%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 0.51%
H: 9.03%
C: 3.79%
treatment risk leukemia car-t t-cell
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
Published: 2021-05-18 (Crawled : 13:15) - biospace.com/
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 5.24%
H: 8.64%
C: 5.32%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -1.41%
H: 12.61%
C: 7.45%
phase 1 trial phase 3 phase 2 car-t t-cell train
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.